Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2026-03-16 00:00:00 ET · period of report 2026-03-13 · accession 0001861684-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-16 | 2026-03-13 | VERA | Young Joseph R | SVP, Fin, CHIEF ACCT OFFCR | M - OptEx | $3.94 | +10.0K | 75.8K | +15% | +$39.4K |
| D | 2026-03-16 | 2026-03-13 | VERA | Young Joseph R | SVP, Fin, CHIEF ACCT OFFCR | M - OptEx | $0.00 | -10.0K | 38.6K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-03-13 | M | A | 10,000 | $3.94 | 75,754 | D | — | — | (F1) Includes 1,032 shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan. |
| 2 | Derivative | Stock Option (right to buy) | 2026-03-13 | M | D | 10,000 | $0.00 | 38,589 | D | $3.94 · — to 2031-04-13 | 10,000 Class A Common Stock | (F2) 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter. |